{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:22Z","timestamp":1792787302673,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["No. BJ-2022-127"],"award-info":[{"award-number":["No. BJ-2022-127"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["No. 2021-I2M-C&T-A-020"],"award-info":[{"award-number":["No. 2021-I2M-C&T-A-020"]}]},{"name":"Beijing Natural Science Foundation","award":["No. 7232137"],"award-info":[{"award-number":["No. 7232137"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,9,12]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR)-T cell has revolutionary efficacy against relapsed\/refractory multiple myeloma (R\/R MM). However, current CAR-T cell therapy has several limitations including long vein-to-vein time and limited viability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 4-1BB-costimulated B-cell maturation antigen (BCMA) CAR-T integrating an independently-expressed OX40 (BCMA-BBZ-OX40) was designed and generated by a traditional manufacturing process (TraditionCART) or instant manufacturing platform (named InstanCART). The tumor-killing efficiency, differentiation, exhaustion, and expansion level were investigated in vitro and in tumor-bearing mice. An investigator-initiated clinical trial was performed in patients with R\/R MM to evaluate the outcomes of both TraditionCART and InstanCART. The primary objective was safety within 1\u2009month after CAR-T cell infusion. The secondary objective was the best overall response rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Preclinical studies revealed that integrated OX40 conferred BCMA CAR-T cells with superior cytotoxicity and reduced exhaustion levels. InstanCART process further enhanced the proliferation and T-cell stemness of BCMA-BBZ-OX40 CAR-T cells. BCMA-BBZ-OX40 CAR-T cells were successfully administered in 22 patients with R\/R MM, including 15 patients with TraditionCART and 7 patients with InstanCART. Up to 50% (11\/22) patients had a high-risk cytogenetic profile and 36% (8\/22) had extramedullary disease. CAR-T therapy caused grade 1\u20132 cytokine release syndrome in 19\/22 (80%) patients, grade 1 neurotoxicity in 2\/22 (9%) patients and led to \u2265grade 3 adverse events including neutropenia (20\/22, 91%), thrombocytopenia (15\/22, 68%), anemia (12\/22, 55%), creatinine increased (1\/22, 5%), hepatic enzymes increased (5\/22, 23%), and sepsis (1\/22, 5%). The best overall response rate was 100%, and 64% (14\/22) of the patients had a complete response or better. The median manufacturing time was shorter for InstanCART therapy (3\u2009days) than for TraditionCART therapy (10 days). Expansion and duration were dramatically higher for InstanCART cells than for TraditionCART cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BCMA-BBZ-OX40 CAR-T cells were well tolerated and exhibited potent responses in patients with R\/R MM. InstanCART shortened the manufacturing period compared to TraditionCART, and improved the cellular kinetics. Our results demonstrated the potency and feasibility of OX40-modified BCMA CAR-T cells using InstanCART technology for R\/R MM therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      This trial was registered at www.clinicaltrials.gov as #\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04537442\">NCT04537442<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009476","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T09:00:20Z","timestamp":1727082020000},"page":"e009476","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04537442","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ting","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing (100730), China"},{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing (100730), China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing (100730), China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Sixth Medical Center of PLA General Hospital, Beijing, China"},{"name":"Beijing Imunopharm Technology Co., Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing (100730), China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing (100730), China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing (100730), China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefei","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing (100730), China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ding","sequence":"additional","affiliation":[{"name":"Beijing Imunopharm Technology Co., Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghua","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Imunopharm Technology Co., Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[{"name":"Beijing Imunopharm Technology Co., Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Lu","sequence":"additional","affiliation":[{"name":"Beijing Imunopharm Technology Co., Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Feng","sequence":"additional","affiliation":[{"name":"Beijing Imunopharm Technology Co., Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[{"name":"Beijing Imunopharm Technology Co., Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing, China"},{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-0216","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing (100730), China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"2025100303464535000_12.9.e009476.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0427-6"},{"key":"2025100303464535000_12.9.e009476.2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405"},{"key":"2025100303464535000_12.9.e009476.3","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and Co-inhibitory Pathways in Autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"2025100303464535000_12.9.e009476.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00191-1"},{"key":"2025100303464535000_12.9.e009476.5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021937"},{"key":"2025100303464535000_12.9.e009476.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600205103"},{"key":"2025100303464535000_12.9.e009476.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.03.012"},{"key":"2025100303464535000_12.9.e009476.8","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.1.558"},{"key":"2025100303464535000_12.9.e009476.9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.10.5808"},{"key":"2025100303464535000_12.9.e009476.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003156"},{"key":"2025100303464535000_12.9.e009476.11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00139","article-title":"Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family Molecules","volume":"4","author":"So","year":"2013","journal-title":"Front Immunol"},{"key":"2025100303464535000_12.9.e009476.12","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091303","article-title":"Co-Stimulatory Receptor Signaling in CAR-T Cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"2025100303464535000_12.9.e009476.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01244-0","article-title":"Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells","volume":"15","author":"Tan","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025100303464535000_12.9.e009476.14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025100303464535000_12.9.e009476.15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ajh.26586","article-title":"A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia","volume":"97","author":"Wang","year":"2022","journal-title":"Am J Hematol"},{"key":"2025100303464535000_12.9.e009476.16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0405"},{"key":"2025100303464535000_12.9.e009476.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2025100303464535000_12.9.e009476.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100303464535000_12.9.e009476.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025100303464535000_12.9.e009476.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.11.016"},{"key":"2025100303464535000_12.9.e009476.21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature New Biol"},{"key":"2025100303464535000_12.9.e009476.22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100303464535000_12.9.e009476.23","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025100303464535000_12.9.e009476.24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2025100303464535000_12.9.e009476.25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112639","article-title":"CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100303464535000_12.9.e009476.26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1276"},{"key":"2025100303464535000_12.9.e009476.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025100303464535000_12.9.e009476.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00688-4","article-title":"Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025100303464535000_12.9.e009476.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100303464535000_12.9.e009476.30","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ajh.27023","article-title":"Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma","volume":"98","author":"Zanwar","year":"2023","journal-title":"Am J Hematol"},{"key":"2025100303464535000_12.9.e009476.31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hon.2958","article-title":"Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease","volume":"40","author":"Li","year":"2022","journal-title":"Hematol Oncol"},{"key":"2025100303464535000_12.9.e009476.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101465","article-title":"Advances in the treatment of extramedullary disease in multiple myeloma","volume":"22","author":"Li","year":"2022","journal-title":"Transl Oncol"},{"key":"2025100303464535000_12.9.e009476.33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100303464535000_12.9.e009476.34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2025100303464535000_12.9.e009476.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005957","article-title":"SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report","volume":"11","author":"McNerney","year":"2023","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:46:56Z","timestamp":1759488416000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,23]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/jitc-2024-009476"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009476","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}